share_log

Cooper Companies | 10-K: FY2024 Annual Report

Cooper Companies | 10-K: FY2024 Annual Report

庫珀醫療 | 10-K：2024財年年報
美股SEC公告 ·  2024/12/06 16:25

Moomoo AI 已提取核心訊息

Cooper Companies reported strong financial results for fiscal 2024, with revenue increasing 8% to $3.9 billion and net income rising 33% to $392.3 million. CooperVision sales grew 8% to $2.6 billion driven by toric and multifocal lenses, while CooperSurgical revenue rose 10% to $1.3 billion supported by office/surgical and fertility segments.Operating income increased 32% to $705.7 million as gross margin held steady at 67%. The company maintained strong cash flow with $709.3 million generated from operations. During the year, Cooper completed strategic acquisitions including Cook Medical's obstetrics assets and obp Surgical to expand its surgical portfolio.Management identified a material weakness in IT controls at CooperSurgical's U.S. operations but has begun implementing remediation steps. The company ended the year with a solid balance sheet showing $2.6 billion in debt and remains well-positioned for continued growth through its diversified portfolio of vision correction and women's health products.
Cooper Companies reported strong financial results for fiscal 2024, with revenue increasing 8% to $3.9 billion and net income rising 33% to $392.3 million. CooperVision sales grew 8% to $2.6 billion driven by toric and multifocal lenses, while CooperSurgical revenue rose 10% to $1.3 billion supported by office/surgical and fertility segments.Operating income increased 32% to $705.7 million as gross margin held steady at 67%. The company maintained strong cash flow with $709.3 million generated from operations. During the year, Cooper completed strategic acquisitions including Cook Medical's obstetrics assets and obp Surgical to expand its surgical portfolio.Management identified a material weakness in IT controls at CooperSurgical's U.S. operations but has begun implementing remediation steps. The company ended the year with a solid balance sheet showing $2.6 billion in debt and remains well-positioned for continued growth through its diversified portfolio of vision correction and women's health products.
庫珀醫療在2024財年報告了強勁的財務業績，營業收入增長8%至39億，凈利潤上升33%至39230萬。庫珀視覺的銷售額增長8%至26億，主要受圓錐和多焦點鏡片的推動，而庫珀外科的營業收入增長10%至13億，得益於辦公室/外科和生育領域。營業收入增長32%至70570萬，毛利率保持在67%的水平。公司維持了強勁的現金流，運營產生了70930萬。在這一年中，庫珀完成了戰略收購，包括庫克醫療的產科資產和obp外科，以擴展其外科產品組合。管理層發現庫珀外科美國業務在信息技術控制方面存在重大薄弱環節，但已開始實施整改措施。公司以穩健的資產負債表結束本年度，顯示負債爲26億，仍然爲持續的增長做好了充分準備，擁有多樣化的視力矯正和女性健康產品組合。
庫珀醫療在2024財年報告了強勁的財務業績，營業收入增長8%至39億，凈利潤上升33%至39230萬。庫珀視覺的銷售額增長8%至26億，主要受圓錐和多焦點鏡片的推動，而庫珀外科的營業收入增長10%至13億，得益於辦公室/外科和生育領域。營業收入增長32%至70570萬，毛利率保持在67%的水平。公司維持了強勁的現金流，運營產生了70930萬。在這一年中，庫珀完成了戰略收購，包括庫克醫療的產科資產和obp外科，以擴展其外科產品組合。管理層發現庫珀外科美國業務在信息技術控制方面存在重大薄弱環節，但已開始實施整改措施。公司以穩健的資產負債表結束本年度，顯示負債爲26億，仍然爲持續的增長做好了充分準備，擁有多樣化的視力矯正和女性健康產品組合。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間